Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Lenalidomide plus R-GDP (R2-GDP) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Final Results of the R2-GDP-GOTEL Trial and Immune Biomarker Subanalysis.
Palazón-Carrión N, Martín García-Sancho A, Nogales-Fernández E, Jiménez-Cortegana C, Carnicero-González F, Ríos-Herranz E, de la Cruz-Vicente F, Rodríguez-García G, Fernández-Álvarez R, Martínez-Banaclocha N, Gumà-Padrò J, Gómez-Codina J, Salar-Silvestre A, Rodríguez-Abreu D, Gálvez-Carvajal L, Labrador J, Guirado-Risueño M, García-Domínguez DJ, Hontecillas-Prieto L, Espejo-García P, Fernández-Román I, Provencio-Pulla M, Sánchez-Beato M, Navarro M, Marylene L, Álvaro-Naranjo T, Casanova-Espinosa M, Sánchez-Margalet V, Rueda-Domínguez A, de la Cruz-Merino L. Palazón-Carrión N, et al. Among authors: de la cruz vicente f. Clin Cancer Res. 2022 Sep 1;28(17):3658-3668. doi: 10.1158/1078-0432.CCR-22-0588. Clin Cancer Res. 2022. PMID: 35727601 Free PMC article. Clinical Trial.
Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma.
Morschhauser F, Fowler NH, Feugier P, Bouabdallah R, Tilly H, Palomba ML, Fruchart C, Libby EN, Casasnovas RO, Flinn IW, Haioun C, Maisonneuve H, Ysebaert L, Bartlett NL, Bouabdallah K, Brice P, Ribrag V, Daguindau N, Le Gouill S, Pica GM, Martin Garcia-Sancho A, López-Guillermo A, Larouche JF, Ando K, Gomes da Silva M, André M, Zachée P, Sehn LH, Tobinai K, Cartron G, Liu D, Wang J, Xerri L, Salles GA; RELEVANCE Trial Investigators. Morschhauser F, et al. N Engl J Med. 2018 Sep 6;379(10):934-947. doi: 10.1056/NEJMoa1805104. N Engl J Med. 2018. PMID: 30184451 Free PMC article. Clinical Trial.
Circulating myeloid-derived suppressor cells and regulatory T cells as immunological biomarkers in refractory/relapsed diffuse large B-cell lymphoma: translational results from the R2-GDP-GOTEL trial.
Jiménez-Cortegana C, Palazón-Carrión N, Martin Garcia-Sancho A, Nogales-Fernandez E, Carnicero-González F, Ríos-Herranz E, de la Cruz-Vicente F, Rodríguez-García G, Fernández-Álvarez R, Rueda Dominguez A, Casanova-Espinosa M, Martínez-Banaclocha N, Gumà-Padrò J, Gómez-Codina J, Labrador J, Salar-Silvestre A, Rodriguez-Abreu D, Galvez-Carvajal L, Provencio M, Sánchez-Beato M, Guirado-Risueño M, Espejo-García P, Lejeune M, Álvaro T, Sánchez-Margalet V, de la Cruz-Merino L; Spanish Lymphoma Oncology Group (GOTEL) and the Spanish Group for Immunobiotherapy of Cancer (GÉTICA); Spanish Lymphoma Oncology Group (GOTEL) and the Spanish Group for Immunobiotherapy of Cancer (GÉTICA); Spanish Lymphoma Oncology Group (GOTEL) and the Spanish Group for Immunobiotherapy of Cancer (GÉTICA). Jiménez-Cortegana C, et al. Among authors: de la cruz vicente f. J Immunother Cancer. 2021 Jun;9(6):e002323. doi: 10.1136/jitc-2020-002323. J Immunother Cancer. 2021. PMID: 34158317 Free PMC article.
CD8+ NKs as a potential biomarker of complete response and survival with lenalidomide plus R-GDP in the R2-GDP-GOTEL trial in recurrent/refractory diffuse large B cell lymphoma.
Hontecillas-Prieto L, García-Domínguez DJ, Palazón-Carrión N, Martín García-Sancho A, Nogales-Fernández E, Jiménez-Cortegana C, Sánchez-León ML, Silva-Romeiro S, Flores-Campos R, Carnicero-González F, Ríos-Herranz E, de la Cruz-Vicente F, Rodríguez-García G, Fernández-Álvarez R, Martínez-Banaclocha N, Gumà-Padrò J, Gómez-Codina J, Salar-Silvestre A, Rodríguez-Abreu D, Gálvez-Carvajal L, Labrador J, Guirado-Risueño M, Provencio-Pulla M, Sánchez-Beato M, Marylene L, Álvaro-Naranjo T, Casanova-Espinosa M, Rueda-Domínguez A, Sánchez-Margalet V, de la Cruz-Merino L. Hontecillas-Prieto L, et al. Among authors: de la cruz vicente f. Front Immunol. 2024 Feb 26;15:1293931. doi: 10.3389/fimmu.2024.1293931. eCollection 2024. Front Immunol. 2024. PMID: 38469299 Free PMC article. Clinical Trial.
Pentostatin plus cyclophosphamide and bexarotene is an effective and safe combination in patients with mycosis fungoides/Sezary syndrome.
Calderon Cabrera C, de la Cruz Vicente F, Marín-Niebla A, Carrillo Cruz E, Rios Herranz E, Espigado Tocino I, Prats Martín C, Falantes JF, Martino Galiana ML, Perez-Simón JA. Calderon Cabrera C, et al. Br J Haematol. 2013 Jul;162(1):130-2. doi: 10.1111/bjh.12320. Epub 2013 Apr 13. Br J Haematol. 2013. PMID: 23581433 Free article. No abstract available.
Role of 18F-FDG-PET/CT in the management of Burkitt lymphoma.
Carrillo-Cruz E, Marín-Oyaga VA, Solé Rodríguez M, Borrego-Dorado I, de la Cruz Vicente F, Quiroga Cantero E, Manzanares Pérez M, Capote FJ, Ramírez Sánchez MJ, Espigado Tocino I, Pérez-Vega H, Vázquez-Albertino R, Pérez-Simón JA. Carrillo-Cruz E, et al. Eur J Haematol. 2015 Jan;94(1):23-30. doi: 10.1111/ejh.12284. Eur J Haematol. 2015. PMID: 24520874
Ofatumumab as part of reduced intensity conditioning in high risk B-cell lymphoma patients: final long-term analysis from a prospective multicenter Phase-II Trial.
Cabrero M, López-Corral L, Jarque I, de la Cruz-Vicente F, Pérez-López E, Valcárcel D, Sanz J, Espigado I, Ortí G, Martín-Calvo C, de la Serna J, Caballero D; Grupo Español de Trasplante Hematopoyético (GETH) and Grupo Español de Linfomas y Trasplante Autólogo (GELTAMO). Cabrero M, et al. Among authors: de la cruz vicente f. Bone Marrow Transplant. 2024 Mar;59(3):359-365. doi: 10.1038/s41409-023-02171-5. Epub 2024 Jan 2. Bone Marrow Transplant. 2024. PMID: 38167647 Clinical Trial.
Role of 18F-FDG-PET/CT in the management of marginal zone B cell lymphoma.
Carrillo-Cruz E, Marín-Oyaga VA, de la Cruz Vicente F, Borrego-Dorado I, Ruiz Mercado M, Acevedo Báñez I, Solé Rodríguez M, Fernández López R, Pérez Vega H, Calderón-Cabrera C, Espigado Tocino I, Pérez-Simón JA, Vázquez-Albertino R. Carrillo-Cruz E, et al. Hematol Oncol. 2015 Dec;33(4):151-8. doi: 10.1002/hon.2181. Epub 2014 Nov 19. Hematol Oncol. 2015. PMID: 25407794
Role of 18F-FDG PET/CT in primary brain lymphoma.
de-Bonilla-Damiá Á, Fernández-López R, Capote-Huelva FJ, de la Cruz-Vicente F, Egea-Guerrero JJ, Borrego-Dorado I. de-Bonilla-Damiá Á, et al. Among authors: de la cruz vicente f. Rev Esp Med Nucl Imagen Mol. 2017 Sep-Oct;36(5):298-303. doi: 10.1016/j.remn.2017.03.006. Epub 2017 Apr 21. Rev Esp Med Nucl Imagen Mol. 2017. PMID: 28438519 English, Spanish.
23 results